Realizing the Potential of Precision Oncology


As we approach the 20th anniversary, in 2018, of the approval of Herceptin, the field of precision oncology has never been more exciting and dynamic, and utility seems to be broadly recognized. Personalized medicines have accounted for over 20% of new molecular entities approved by FDA in each of the last 3 years, according to the Personalized Medicine Coalition and biomarker-
based stratification is currently utilized in 30% of late-phase trials.

View PDF